Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DNS58L
|
|||
| Drug Name |
SRX246
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Huntington disease [ICD-11: 8A01.10; ICD-10: G10; ICD-9: 294.1, 333.4] | Phase 2 | [1] | |
| Post-traumatic stress disorder [ICD-11: 6B40; ICD-10: F43.1, F62.0; ICD-9: 309.81] | Phase 2 | [2] | ||
| Intermittent explosive disorder [ICD-11: 6C73] | Phase 1/2 | [3] | ||
| Anxiety disorder [ICD-11: 6B00-6B0Z] | Phase 1 | [4] | ||
| Fear-related disorder [ICD-11: 6B0Z] | Phase 1 | [4] | ||
| Company |
Azevan Pharmaceuticals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Vasopressin V1a receptor (V1AR) | Target Info | Antagonist | [5] |
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Vascular smooth muscle contraction | ||||
| Reactome | Vasopressin-like receptors | |||
| G alpha (q) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| Peptide GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02507284) Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease. U.S. National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT02733614) Proof-of-concept Study to Assess the Efficacy and Safety of SRX246 in Adults With PTSD. U.S. National Institutes of Health. | |||
| REF 3 | ClinicalTrials.gov (NCT02055638) Safety, Tolerability and Activity of SRX246 in Adults With Intermittent Explosive Disorder (AVN009). U.S. National Institutes of Health. | |||
| REF 4 | ClinicalTrials.gov (NCT02922166) Effects of SRX246 on an Experimental Model of Fear and Anxiety in Humans. U.S. National Institutes of Health. | |||
| REF 5 | Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington's Disease Patients-A Randomized Phase 2 Clinical Trial. J Clin Med. 2020 Nov 16;9(11):3682. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.